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Abstract 
A fifty-eight year old male patient presented to the 
ophthalmic department with a 3 day history of reduced 
visual acuity, blurred vision and floaters, associated with 
recent lethargy, headaches and behavioural changes. 
Fundal examination revealed a bilateral vitritis. Steroid 
therapy was started. MRI of the brain revealed multiple 
hypodense and hyperdense lesions. Vitrectomy was 
performed in view of the poor response to steroids. A 
biopsy showed non-hodgkin B-Cell lymphoma. The 
patient was started on intravenous Methotrexate and 
Cytarabine. Repeat vitreous cavity biopsies were 
performed in order to assess response to therapy. All 
biopsies to date have revealed evidence of on-going 
lymphoma. 
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Background 
Primary CNS Lymphoma is a high-grade extra 
nodal non-Hodgkin B-cell neoplasm that commonly 
masquerades as benign conditions that mimic an uveitis-
like picture. It is to our knowledge that this is the first 
reported case on the Maltese Islands in which vitreal 
metastases have occurred. Due to the location of the 
lesions, stereotactic brain biopsies were not possible to 
perform in order to make a diagnosis. Vitrectomy served 
as both a diagnostic and therapeutic tool, where repeat 
vitreous cavity biopsies have also been used as a means 
of assessing response to therapy. Fortunately, all 
samples so far have confirmed the presence of 
lymphoma, making vitrectomy the only accurate and 
feasible means of assessing prognosis and response to 
therapy despite the well-documented poor positive 
predictive value of such techniques due to the fragility of 
the lymphoma cells in question.  
 
Case presentation  
A 58 year old male patient presented to the accident 
and emergency department with a three day history of 
left sided tunnel vision, distortion, blurring and floaters.  
There was no ocular pain or tenderness. Visual acuity on 
examination was 6/9 bilaterally.  Pupils were reactive 
with no relative afferent pupillary defect seen. 
Fundoscopy revealed mild vitritis on the right and severe 
vitritis on the left.  Intra-ocular pressures were 18mmHg 
bilaterally.The patient was started on topical steroids.   
Review 6 weeks later revealed no change in the 
degree of vitritis. There was a quiet anterior segment and 
no evidence of retinitis or choroiditis. Visual acuity 
remained unchanged.  B scan of the retina was 
unremarkable except for a very hazy vitreous. Subtenon 
Triamcinolone (Kenalog), with a view for follow up was 
given. An MR Brain was done. 
Two weeks later, the patient was advised to return 
to the emergency department in view of his MR Brain 
findings. A thorough history revealed the patient had a 
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two week history of worsening confusion associated 
with weakness, lethargy, headaches and night sweats. 
Relatives noted a gradual change in behaviour. 
Neurological examination was grossly normal. Repeat 
MR Brain on admission to A&E revealed no changes 
from the previous MR Brain. Lumbar punctures were 
insignificant.  
A working diagnosis of lymphoma was made. 
Multiple sclerosis was also being considered. A concrete 
diagnosis was not possible without histological samples.  
The diagnosis was clinched when a left vitreous 
body biopsy after a pars plana vitrectomy revealed B-
lymphocystoid lymphocytes within the vitreous, in 
keeping with a high grade diffuse Non-hodgkin B-Cell 
lymphoma.   
A central line was inserted and the patient was 
started on high-dose intravenous methotrexate and 
Cytarabine according to the Ferreri Protocol. Repeat 
vitreous cavity samples were taken in order to assess the 
response to therapy. Unfortunately due to the aggressive 
nature of the lymphoma, repeat vitreous biopsies 
continued to show evidence of ongoing lymphoma. 
 
Investigations 
Slit lamp examination usually reveals vitreous cells 
forming clumps or sheets in the posterior segment. 
Fundus examination commonly reveals large, multifocal, 
bilateral, well-demarcated, yellow-coloured subretinal 
infiltrates.1 Unfortunately no such lesions were seen in 
this case (Fig 1). 
 
Figure 1: Fundoscopy: Posterior segment photo showing hazy vitreous with poor fundal details 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: MR Brain: (A) Axial Diffusion Weighted Image (DWI) showing restricted diffusion predominantly in the frontal 
areas (B) Axial T2FLAIR showing white matter hyperintensities (C) Axial T1 with contrast showing enhancement of the 
left frontal lesions 
 
 
 
 
 
 
 
 
 
 
Figure 3 - MR Brain at the level of the thalami: (A) Axial T2 FLAIR (B) Axial T1 with contrast showing a 1.5cm 
enhancing lesion  in the right 
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Fluorescein angiography may show 
hypofluorescent or hyperfluorescent lesions. 2 No such 
lesions were seen in this case. 
Ultrasound commonly reveals vitreous debris, 
choroidoscleral thickening or chorioretinal lesions. 3  No 
lesions were found on US examination.  
Baseline blood investigations such as CBC, CRP, 
ESR, routine blood biochemistries as well as a CXR 
were found to be within normal limits.  
MRI revealed hyperdense lesions in T1-weighted 
images and hypodense lesions within deep structures of 
the brain when using T2-weighted sequencing (Fig 2-3).3 
Lymphoma cells may also be identified in the 
cerebrospinal (CSF) fluid in 25 % of cases. Lymphoma 
cells are usually large and pleomorphic with a scanty 
basophilic cytoplasm. 4 No cells were isolated when 
lumbar punctures were performed.  
Cytometry with Cytospin preparation was carried 
out using Wescor Stainer, while the remaining sample 
was used for Flow Cytometric (FC) analysis. The cells 
were stained with the following fluorochrome-labelled 
monoclonal antibodies: CD20FITC, CD19APC, 
CD10PE, CD22APC, CD79a, CD138, CD38, CD5FITC 
CD4PE, CD8FITC, CD3APC and CD45PerCP. 
Examination of the cytospin preparation showed the 
presence of a homogenous cell population composed of 
medium to large sized plasmacytoid cells with scanty 
and bluish cytoplasm. (Fig 4).FC evaluation showed a 
population of cells with moderate expression of CD45 
and low Side Scatter. When gated on the cell population 
the cells showed weak positivity to B-cell markers 
CD19, CD20 and CD38, moderate positivity to CD22 
and CD79a and light chain restriction with strong 
positivity to Lambda but no expression of Kappa light 
chain. CD10 was negative. All T-cell markers, CD5, 
CD3, CD4 and CD8 were negative thus ruling out T-cell 
phenotype and also CD138 showed lack of positivity 
excluding a plasmacytoid malignancy.  
 
Figure 4: Cells show medium expression of CD45 and moderate Side Scatter 
 
 
 
 
 
 
 
 
 
 
Treatment  
The initial management on presentation included 
the use of high dose steroids. Unfortunately there was no 
response and no change in the degree of vitritis. 
On confirmation of the diagnosis the patient was 
started on high-dose intravenous methotrexate and 
Cytarabine according to the Ferreri Protocol. Repeat 
vitreous cavity samples were taken in order to assess 
response to therapy. Unfortunately, owing to the 
aggressive nature of the lymphoma, biopsies showed 
evidence of on-going lymphoma.  
Maintenance treatment was alerted from a monthly 
dose of methotrexate to a biweekly regimen. The 
combined use of MTX and radiation has been shown to 
decrease recurrence rates. However, it is associated with 
a 60% risk of developing dementia or 
leukoencephalopathy. Such therapy is currently being 
considered.  
 
Outcome and follow up 
Follow up is crucial, usually undertaken on a 
monthly basis with repeat MRI examination or CSF 
analysis from lumbar puncture. The following may 
constitute a failure in treatment: 
x Greater than 25% enlargement of previous areas of 
gadolinium-contrast enhancement 
x Appearance of new contrast-enhancing lesions 
x Appearance of malignant cells in the CSF or 
vitreous if not previously present 
If treatment does in fact fail, there are several 
options that may be used. Initially, maintenance 
treatment may be altered from a monthly dose of 
methotrexate to a biweekly regimen.  Radiation therapy 
may be implemented, often being the best second-line 
anti-PCNSL treatment. One may also attempt 
combination therapy. The combined use of MTX and 
radiation has been shown to decrease recurrence rates.  
Intravitreal methotrexate is also an option. This however 
is not being considered as of yet due to the uncertainty 
of any long term benefits keeping the aggressive and 
recurrent nature of the lymphoma in question. 
A vitrectomy was planned and performed on the 
accompanying eye. Vitreous biopsy also revealed 
evidence of lymphoma metastasis. 
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Repeated vitreous cavity samples are being taken in 
order to assess response to the Ferreri Protocol 
implemented. Unfortunately, due to the aggressive 
nature of the lymphoma, response has been poor. 
Repeated samples have shown evidence of ongoing 
disease.   
Repeat MRIs did not show marked regression of the 
lesions. That being said, the patient is clinically stable 
and has not suffered any set backs. Regular neurological 
outpatients follow up showed no new focal or 
widespread neurological deficit.  
 
Discussion  
PCNSL accounts for about 4-6% of all primary 
brain neoplasms and 2% of all extranodal lymphomas. 5 
It occurs mostly in patients aged between 50-60 years 
Ocular dissemination occurs in 15-25% of patients being 
bilateral in 80% of cases. 6  
The average duration of symptoms prior to 
diagnosis is usually 3 months. PCNSL with intra-ocular 
involvement commonly presents in older patients with a 
non-specific chronic uveitis like picture which is 
unresponsive to topical and systemic corticosteroid 
treatment.  
Ocular symptoms tend to precede cerebral 
symptoms by months or years in many cases. 7 
Behavioural change is the most common neurological 
symptom at presentation, occurring in 25-75% of 
patients. 8 Initial assessment of MR Brain favoured a 
demyelinating or inflammatory pathology.  This was 
excluded after repeat MR Brains showed no significant 
interval change.  
Adequate management and treatment of such 
patients is dependent on early, accurate and timely 
diagnosis. Corticosteroids must be avoided during the 
initial workup and management because their 
administration may have a direct antitumor effect. 
Similarly, corticosteroids should be avoided during 
chemotherapy as they stimulate repair of the blood-brain 
barrier, decreasing the delivery of methotrexate into the 
brain parenchyma. 9 
The mainstay of treatment is chemotherapy.  
However, the main difficulty with using chemotherapy 
is the blood-ocular barrier. 10 Studies show that systemic 
high dose chemotherapy resulted in relatively low drug 
levels in the vitreous, implicating the importance to focal 
ocular treatment. 11 Studies also show that intrathecal 
MTX may also be beneficial when combined to systemic 
MTX treatement. 12 
It is crucial that ocular disease is seen to because if 
left untreated, it may act as a reservoir of persistent 
active disease. 13 Intravitreal MTX is able to maintain 
cytotoxic levels in the vitreous for hours as opposed to 
systemic MTX, also resulting in less complications. 
Intravitreal MTX has not been initiated in the patient in 
question but is being discussed as the next possible 
option in management.  
While intravitreal MTX should be added to the 
standard systemic chemotherapy regimen, ocular 
treatment simply appears to improve local control, but 
has no proven long term survival benefit. 14 
Unfortunately, prognosis remains poor, commonly 
as a result of the high degree of recurrence and late 
diagnosis. 15  
 
Learning points/take home messages  
1. CNS lymphoma with vitreal metastasis may easily 
masquerade as a benign uveitis.  
 
2. Lymphoma should be one of the differential 
diagnosis in cases of uveitis resistant to steroid 
treatment. 
 
3. A multidisciplinary approach to patient care and 
management is vital in the proper follow up and 
treatment of such cases. Adequate co-operation 
between the ophthalmic and neurological 
department was necessary. 
 
4. Vitreous samples should be handled with care to 
protect fragile lymphoma cells. Unfortunately, 40% 
of vitrectomy specimens remain non-diagnostic 
after corticosteroid use as they are cytolytic to 
lymphoma cells. 
 
5. A multidisciplinary team is essential. Neurological 
and ophthalmic follow up must be accompanied by 
adequate oncological input in order to keep up to 
date with the attest chemotherapeutic protocols and 
guidelines. Social services also play a role in 
making sure the patient is comfortable and is 
making use of all the services available.  
 
Patient’s perspective 
“Things happened very fast. Treatment was started 
straight away but it was not the best treatment. More 
tests were needed to finalize the diagnosis. I was happy 
with the way I was treated and I thank everyone for 
taking care of me. I worry because I am always in and 
out of hospital and I can never get rid of this condition. I 
underwent a vitrectomy in my other eye in order to help 
with the hazy vision. To be honest, my vision was the 
most important issue and had it not been for that, I do 
not think we would have started to treat my cancer 
condition so early because I felt fine.” 
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